Sajitha Sachchithanantham
Overview
Explore the profile of Sajitha Sachchithanantham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bristogiannis S, Khwaja J, Lwin Y, Wechelaker A, Wisniowski B, Mahmood A, et al.
Br J Haematol
. 2023 May;
202(2):289-293.
PMID: 37194132
Systemic AL amyloidosis is an incurable condition with various presentations and may cause multiple complications related to organ involvement. As survival has improved, disease and therapy-related quality of life (QoL)...
2.
Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al.
Eur Heart J
. 2022 Oct;
43(45):4722-4735.
PMID: 36239754
Aims: To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume...
3.
Cohen O, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, et al.
Heart
. 2022 Jun;
108(20):1616-1622.
PMID: 35764371
Objectives: In AL amyloidosis, organ response assessment is based on surrogates (eg, cardiac biomarkers). An objective functional test, such as the 6 min walk test (6MWT), capturing overall clinical improvement,...
4.
Ravichandran S, Mahmood S, Wisniowski B, Sachchithanantham S, Popat R, Lachmann H, et al.
Br J Haematol
. 2022 May;
198(2):328-332.
PMID: 35509237
Depth of response is the critical determinant of prognosis in amyloid light-chain (AL) amyloidosis. Here, we aim to identify patients who are unlikely to improve response based on analysis of...
5.
Cohen O, Blakeney I, Law S, Ravichandran S, Gilbertson J, Rowczenio D, et al.
Amyloid
. 2022 May;
29(4):237-244.
PMID: 35502644
Introduction: Hereditary apolipoprotein A-I (AApoAI) amyloidosis is a rare heterogeneous disease with variable age of onset and organ involvement. There are few series detailing the natural history and outcomes of...
6.
Cohen O, Ismael A, Pawarova B, Manwani R, Ravichandran S, Law S, et al.
Eur Heart J
. 2021 Sep;
43(4):333-341.
PMID: 34472567
Aims: Cardiac involvement, a major determinant of prognosis in AL (light-chain immunoglobulin) amyloidosis, is characterized by an impairment of longitudinal strain (LS%). We sought to evaluate the utility of LS%...
7.
Rezk T, Salota R, Gan J, Lachmann H, Fontana M, Siew K, et al.
Br J Haematol
. 2021 Aug;
194(6):1016-1023.
PMID: 34374069
Renal risk stratification in systemic immunoglobulin light-chain (AL) amyloidosis is according to estimated glomerular filtration rate (eGFR) and urinary protein creatinine ratio (uPCR), the latter attributed to glomerular dysfunction, with...
8.
Quarta C, Zheng J, Hutt D, Grigore S, Manwani R, Sachchithanantham S, et al.
Eur Heart J Cardiovasc Imaging
. 2021 Jul;
22(11):1304-1311.
PMID: 34254119
Aims: Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA). A proportion of patients with immunoglobulin light chain (AL)...
9.
Ravichandran S, Cohen O, Law S, Sachchithanantham S, Mahmood S, Foard D, et al.
Br J Haematol
. 2021 Jun;
194(3):587-597.
PMID: 34189728
Systemic immunoglobulin light chain amyloidosis (AL) is an incurable disorder, and the natural history is incompletely understood. In this study, we describe its natural history based on an analysis of...
10.
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Ravichandran S, Cohen O, Law S, Foard D, Fontana M, Martinez-Naharro A, et al.
Blood Cancer J
. 2021 Jun;
11(6):118.
PMID: 34155191
The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here...